Advertisement

APOBEC as an Endogenous Mutagen in Cancers of the Head and Neck

  • Tomoaki Sasaki
  • Natalia Issaeva
  • Wendell G. Yarbrough
  • Karen S. Anderson
Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) proteins are a family of cytidine deaminases that play important roles in diverse physiological processes in humans. APOBEC3-driven cytidine deamination results in a C-to-U conversion in target nucleotides, classifying this biological activity as a DNA-/RNA-editing mechanism. In recent years, biochemical, cellular, and bioinformatics studies have supported a role for APOBEC3 proteins in the etiology of human cancers, based on their ability to mutate genomic DNA. In this chapter, we provide a thorough review of recent studies that have implicated APOBEC3 in a number of diverse cancers, including head and neck cancers. These studies suggest that APOBEC3-dependent mutations are most associated with squamous cell carcinomas of the head and neck and may be linked to human papillomavirus (HPV) expression and production of neoantigens. Cell-based and structural evidence corroborates the initial bioinformatics data on APOBEC3 function. In conclusion, we raise several prospects for targeted therapeutic avenues including potential immunotherapy options that can leverage neoantigens generated from APOBEC activity.

Keywords

APOBEC3 Cytidine deaminases Mutations Mutational burden SCCHN Head and neck squamous cell carcinoma Neoantigens DNA editing Human papillomavirus Targeted therapy Immunotherapy 

References

  1. 1.
    Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science (New York, NY). 1993;260:1816–9.CrossRefGoogle Scholar
  2. 2.
    Navaratnam N, et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem. 1993;268:20709–12.Google Scholar
  3. 3.
    Driscoll DM, Zhang Q. Expression and characterization of p27, the catalytic subunit of the apolipoprotein B mRNA editing enzyme. J Biol Chem. 1994;269:19843–7.PubMedGoogle Scholar
  4. 4.
    Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 2002;418:99–103.  https://doi.org/10.1038/nature00862.CrossRefGoogle Scholar
  5. 5.
    Muramatsu M, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999;274:18470–6.CrossRefGoogle Scholar
  6. 6.
    Muramatsu M, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553–63.CrossRefGoogle Scholar
  7. 7.
    Jarmuz A, et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 2002;79:285–96.  https://doi.org/10.1006/geno.2002.6718.CrossRefGoogle Scholar
  8. 8.
    Chiu YL, Greene WC. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 2006;27:291–7.  https://doi.org/10.1016/j.it.2006.04.003.CrossRefPubMedGoogle Scholar
  9. 9.
    Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell. 2002;10:1247–53.CrossRefGoogle Scholar
  10. 10.
    Salter JD, Bennett RP, Smith HC. The APOBEC protein family: united by structure, divergent in function. Trends Biochem Sci. 2016;41:578–94.  https://doi.org/10.1016/j.tibs.2016.05.001.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zhang H, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–8.  https://doi.org/10.1038/nature01707.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mangeat B, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99–103.  https://doi.org/10.1038/nature01709.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hakata Y, Landau NR. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem. 2006;281:36624–31.  https://doi.org/10.1074/jbc.M604980200.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shi K, Carpenter MA, Kurahashi K, Harris RS, Aihara H. Crystal structure of the DNA deaminase APOBEC3B catalytic domain. J Biol Chem. 2015;290:28120–30.  https://doi.org/10.1074/jbc.M115.679951.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Belanger K, Savoie M, Rosales Gerpe MC, Couture JF, Langlois MA. Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res. 2013;41:7438–52.  https://doi.org/10.1093/nar/gkt527.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Navarro F, et al. Complementary function of the two catalytic domains of APOBEC3G. Virology. 2005;333:374–86.  https://doi.org/10.1016/j.virol.2005.01.011.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009;5:e1000330.  https://doi.org/10.1371/journal.ppat.1000330.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Opi S, et al. Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol. 2006;80:4673–82.  https://doi.org/10.1128/jvi.80.10.4673-4682.2006.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yu Q, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004;11:435–42.  https://doi.org/10.1038/nsmb758.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Burns MB, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494:366–70.  https://doi.org/10.1038/nature11881.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–50.  https://doi.org/10.1038/nature00939.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (New York, NY). 2003;300:1112.  https://doi.org/10.1126/science.1083338.CrossRefGoogle Scholar
  23. 23.
    Harris RS, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mariani R, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114:21–31.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mehle A, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem. 2004;279:7792–8.  https://doi.org/10.1074/jbc.M313093200.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Shirakawa K, et al. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology. 2006;344:263–6.  https://doi.org/10.1016/j.virol.2005.10.028.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zheng YH, et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol. 2004;78:6073–6.  https://doi.org/10.1128/jvi.78.11.6073-6076.2004.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol. 2006;80:10522–33.  https://doi.org/10.1128/jvi.01123-06.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol. 2005;79:8201–7.  https://doi.org/10.1128/jvi.79.13.8201-8207.2005.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yu Q, et al. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem. 2004;279:53379–86.  https://doi.org/10.1074/jbc.M408802200.CrossRefGoogle Scholar
  31. 31.
    Doehle BP, Schafer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology. 2005;339:281–8.  https://doi.org/10.1016/j.virol.2005.06.005.CrossRefGoogle Scholar
  32. 32.
    Bogerd HP, et al. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A. 2006;103:8780–5.  https://doi.org/10.1073/pnas.0603313103.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 2006;34:89–95.  https://doi.org/10.1093/nar/gkj416.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Muckenfuss H, et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem. 2006;281:22161–72.  https://doi.org/10.1074/jbc.M601716200.CrossRefPubMedGoogle Scholar
  35. 35.
    Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem. 2006;281:16837–41.  https://doi.org/10.1074/jbc.M602367200.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen KM, et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature. 2008;452:116–9.  https://doi.org/10.1038/nature06638.CrossRefPubMedGoogle Scholar
  37. 37.
    Holden LG, et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature. 2008;456:121–4.  https://doi.org/10.1038/nature07357.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Harjes E, et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol. 2009;389:819–32.  https://doi.org/10.1016/j.jmb.2009.04.031.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Shandilya SM, et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (London, England : 1993). 2010;18:28–38.  https://doi.org/10.1016/j.str.2009.10.016.CrossRefGoogle Scholar
  40. 40.
    Bohn MF, et al. The ssDNA mutator APOBEC3A is regulated by cooperative dimerization. Structure (London, England: 1993). 2015;23:903–11.  https://doi.org/10.1016/j.str.2015.03.016.CrossRefGoogle Scholar
  41. 41.
    Shi K, et al. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct Mol Biol. 2017;24:131–9.  https://doi.org/10.1038/nsmb.3344.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kouno T, et al. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nat Commun. 2017;8:15024.  https://doi.org/10.1038/ncomms15024.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Xiao X, Li SX, Yang H, Chen XS. Crystal structures of APOBEC3G N-domain alone and its complex with DNA. Nat Commun. 2016;7:12193.  https://doi.org/10.1038/ncomms12193.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Nik-Zainal S, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–93.  https://doi.org/10.1016/j.cell.2012.04.024.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.  https://doi.org/10.1038/nature12477.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Chan K, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47:1067.  https://doi.org/10.1038/ng.3378.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45:977–83.  https://doi.org/10.1038/ng.2701.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Leonard B, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013;73:7222–31.  https://doi.org/10.1158/0008-5472.can-13-1753.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Roberts SA, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45:970–6.  https://doi.org/10.1038/ng.2702.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Taylor BJ, et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife. 2013;2:e00534.  https://doi.org/10.7554/eLife.00534.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007;3:e63.  https://doi.org/10.1371/journal.pgen.0030063.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Long J, et al. A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 2013;105:573–9.  https://doi.org/10.1093/jnci/djt018.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Xuan D, et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis. 2013;34:2240–3.  https://doi.org/10.1093/carcin/bgt185.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Nik-Zainal S, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014;46:487–91.  https://doi.org/10.1038/ng.2955.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Middlebrooks CD, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48:1330–8.  https://doi.org/10.1038/ng.3670.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Harris RS. Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Med. 2013;5:87.  https://doi.org/10.1186/gm490.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Roberts SA, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 2012;46:424–35.  https://doi.org/10.1016/j.molcel.2012.03.030.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Hoopes JI, et al. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep. 2016;14:1273–82.  https://doi.org/10.1016/j.celrep.2016.01.021.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Sakofsky CJ, et al. Break-induced replication is a source of mutation clusters underlying kataegis. Cell Rep. 2014;7:1640–8.  https://doi.org/10.1016/j.celrep.2014.04.053.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Chen J, Miller BF, Furano AV. Repair of naturally occurring mismatches can induce mutations in flanking DNA. eLife. 2014;3:e02001.  https://doi.org/10.7554/eLife.02001.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kazanov MD, et al. APOBEC-induced cancer mutations are uniquely enriched in early-replicating, gene-dense, and active chromatin regions. Cell Rep. 2015;13:1103–9.  https://doi.org/10.1016/j.celrep.2015.09.077.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Wilson DM 3rd, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair. 2007;6:544–59.  https://doi.org/10.1016/j.dnarep.2006.10.017.CrossRefPubMedGoogle Scholar
  63. 63.
    Ross AL, Sale JE. The catalytic activity of REV1 is employed during immunoglobulin gene diversification in DT40. Mol Immunol. 2006;43:1587–94.  https://doi.org/10.1016/j.molimm.2005.09.017.CrossRefPubMedGoogle Scholar
  64. 64.
    Jansen JG, et al. Strand-biased defect in C/G transversions in hypermutating immunoglobulin genes in Rev1-deficient mice. J Exp Med. 2006;203:319–23.  https://doi.org/10.1084/jem.20052227.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Fanourakis G, et al. Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas. Exp Mol Pathol. 2016;101:314–9.  https://doi.org/10.1016/j.yexmp.2016.11.001.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Zhang L, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet. 2015;96:597–611.  https://doi.org/10.1016/j.ajhg.2015.02.017.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Liu W, et al. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. JCI Insight. 2016;1:e88755.  https://doi.org/10.1172/jci.insight.88755.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Gleber-Netto FO, et al. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer. 2017;124:84.  https://doi.org/10.1002/cncr.31063.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Burtness B. The tumor genome in human immunodeficiency virus-related head and neck cancer: exploitable targets? Cancer. 2017.  https://doi.org/10.1002/cncr.31059.
  70. 70.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14:467–75.  https://doi.org/10.1158/1055-9965.epi-04-0551.CrossRefGoogle Scholar
  71. 71.
    Gillison ML, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.  https://doi.org/10.1093/jnci/djn025.CrossRefPubMedGoogle Scholar
  72. 72.
    Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science (New York, NY). 2008;320:230–3.  https://doi.org/10.1126/science.1153201.CrossRefGoogle Scholar
  73. 73.
    Wang Z, et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol. 2014;88:1308–17.  https://doi.org/10.1128/jvi.03091-13.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Ahasan MM, et al. APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity. Biochem Biophys Res Commun. 2015;457:295–9.  https://doi.org/10.1016/j.bbrc.2014.12.103.CrossRefPubMedGoogle Scholar
  75. 75.
    Warren CJ, et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015;89:688–702.  https://doi.org/10.1128/jvi.02383-14.CrossRefPubMedGoogle Scholar
  76. 76.
    Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014;7:1833–41.  https://doi.org/10.1016/j.celrep.2014.05.012.CrossRefPubMedGoogle Scholar
  77. 77.
    Henderson S, Chakravarthy A, Fenton T. When defense turns into attack: Antiviral cytidine deaminases linked to somatic mutagenesis in HPV-associated cancer. Mol Cell Oncol. 2014;1:e29914.  https://doi.org/10.4161/mco.29914.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Vieira VC, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. mBio. 2014;5.  https://doi.org/10.1128/mBio.02234-14.
  79. 79.
    Barretina J, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715–21.  https://doi.org/10.1038/ng.619.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A. 2008;105:2652–7.  https://doi.org/10.1073/pnas.0712169105.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Adelstein D, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Cancer Netw: JNCCN. 2017;15:761–70.  https://doi.org/10.6004/jnccn.2017.0101.CrossRefGoogle Scholar
  82. 82.
    Scott L, Azacitidine J. A review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs. 2016;76:889–900.  https://doi.org/10.1007/s40265-016-0585-0.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Biktasova A, et al. Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer. Clin Cancer Res. 2017;23:7276.  https://doi.org/10.1158/1078-0432.ccr-17-1438.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Buisson R, Lawrence MS, Benes CH, Zou L. APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition. Cancer Res. 2017;77:4567–78.  https://doi.org/10.1158/0008-5472.can-16-3389.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Boichard A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology. 2017;6:e1284719.  https://doi.org/10.1080/2162402x.2017.1284719.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Mullane SA, et al. Correlation of apobec mrna expression with overall survival and pd-l1 expression in urothelial carcinoma. Sci Rep. 2016;6:27702.  https://doi.org/10.1038/srep27702.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.  https://doi.org/10.1158/1535-7163.mct-14-0983.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (New York, NY). 2015;348:69–74.  https://doi.org/10.1126/science.aaa4971.CrossRefGoogle Scholar
  89. 89.
    Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348:124–8.  https://doi.org/10.1126/science.aaa1348.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Tomoaki Sasaki
    • 1
  • Natalia Issaeva
    • 1
  • Wendell G. Yarbrough
    • 1
  • Karen S. Anderson
    • 1
  1. 1.Yale University School of MedicineNew HavenUSA

Personalised recommendations